Ipamorelin is a selective agonist of the growth hormone secretagogue receptor (GHSR-1a), derived from GHRP-1. The original characterization study found it stimulates pulsatile growth hormone release a...
Ipamorelin is a selective agonist of the growth hormone secretagogue receptor (GHSR-1a), derived from GHRP-1. The original characterization study found it stimulates pulsatile growth hormone release at potency comparable to other GH secretagogues, but — unlike earlier-generation compounds in its class — without significantly elevating ACTH, cortisol, or prolactin above GHRH-stimulated levels, even at supra-effective doses.
Journal of Pharmacology and Experimental Therapeutics · 2009
Repeated ipamorelin dosing significantly increased fecal output, food intake, and weight gain in a rat postoperative ileus model, and a single dose reduced time to first bowel movement.
View Source →Neuro Endocrinology Letters · 2004
Ex vivo pancreatic fragments from normal and diabetic rats showed increased insulin secretion on ipamorelin exposure, blocked by calcium-channel and adrenergic-receptor antagonists.
View Source →European Journal of Endocrinology · 1998
The original characterization study: ipamorelin stimulated GH release with potency similar to GHRP-6, but unlike other secretagogues did not elevate ACTH or cortisol above GHRH-stimulated levels even at supra-effective doses.
View Source →-01M0DXR1X2VPVMY9M2ZZNGVSN3.png)